A follow-up project on the GADinLADA trial to test for the continued impact of HLA-DR3DQ2 on diabetes status and immune parameters 3 years after treatment with intranodal GAD-alum.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509021-53-00

Enrollment

Registered

2024-05-03

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent Autoimmune Diabetes in Adults (LADA)

Brief summary

Change in diabetes status variables (beta cell insulin secretion capacity and metabolic control) 3 years after treatment with GAD-alum (IMP) in the GADinLADA study, compared to baseline and the end of study (i.e., 12 months after baseline) in GADinLADA.

Interventions

DRUGDiamyd

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in diabetes status variables (beta cell insulin secretion capacity and metabolic control) 3 years after treatment with GAD-alum (IMP) in the GADinLADA study, compared to baseline and the end of study (i.e., 12 months after baseline) in GADinLADA.	—

Countries

Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026